ADIENNE is developing a portfolio of Antibody Drug Conjugates (ADC) with the monoclonal antibody Begelomab® and toxins through different conjugation strategies to treat malignant mesotheliomas. Surgery is not an option for the majority of patients due to the diffuse spreading growth of this neoplasm. Despite increasing knowledge of the biology of this tumor, patients with malignant mesothelioma have a poor prognosis, with estimated median survival times of only 4-12 months. Compared to traditional chemotherapy the antibody-based molecular platform enables selective delivery of a potent cytotoxic payload to target cancer cells, resulting in improved efficacy, reduced systemic toxicity, more favourable pharmacokinetics and pharmacodynamics properties and improved biodistribution.
